United States· US:85043-030_b8da8614-75a8-453c-be31-0568da16a3b9

Vabrinty

A leuprorelin product containing leuprolide acetate, registered in United States by URONOVA PHARMACEUTICALS, INC.. The same ATC class is registered in 13 of our 19 countries.

ATC L02AE02Orange BookUS label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedVabrintyATCL02AE02REGISTER NO.US:85043-030_b8da8614…PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Leuprorelin is registered in 13 of 19 countries.

Countries holding a registration under ATC L02AE02 (leuprorelin), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose

Leuprorelin · ATC L02AE02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of leuprorelin costs, country by country.

Normalised to the WHO defined daily dose (1 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Leuprorelin · price per daily dose (1 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$34.21
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
Leuprolide acetate
Manufacturer
URONOVA PHARMACEUTICALS, INC.
Country
United States (US)
ATC code
L02AE02
ATC class
Leuprorelin
Defined daily dose
1 mg, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 12, 2026

Packs & prices · 1

  • ndc11
    8504303003
    1 SYRINGE in 1 CARTON (85043-030-03) / .5 mL in 1 SYRINGE

Regulatory notes

UNII (FDA substance ID)
37JNS02E7V
LEUPROLIDE ACETATE
RxCUI 203217
Orange Book
N021488
DailyMed SPL labels
1 version tracked

Interactions

320 interactions on record for leuprorelin.

Graded by severity as the source publishes them — 69 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Leuprorelin · interactions on record

320 records

  • 69 severe
  • 248 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Leuprorelin in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All leuprorelin products

Authorised across Europe · EMA

The same active substance is authorised in 31 EEA countries. Names it is sold under:

  • Austria · Eligard Depot, Enantone Monats-Depot
  • Belgium · Depo-Eligard
  • Bulgaria · Елигард, Лутрат Депо
  • Cyprus · Eligard
  • Czechia · Eligard, Leptoprol
  • Germany · Eligard, Enantone Monats-Depot
  • Denmark · Eligard, Leuprorelin Sandoz
  • Estonia · Eligard
  • Spain · Eligard Semestral, Eligard Trimestral
  • Finland · Eligard, Enanton Depot Dual
  • France · Eligard, Enantone Lp
  • United Kingdom (Northern Ireland) · Prostap 3 Dcs, Prostap Pd Dcs
  • Greece · Deplanda, Elityran
  • Croatia · Eligard, Lerin
  • Hungary · Eligard, Leuprorelin Pharmacenter
  • Ireland · Eligard, Leuprex 3
  • Iceland · Camcevi, Eligard
  • Italy · Eligard, Enantone
  • Liechtenstein · Camcevi
  • Lithuania · Eligard
  • Luxembourg · Depo-Eligard, Leugon
  • Latvia · Eligard, Leptoprol
  • Malta · Deplanda
  • Netherlands · Eligard, Leuproreline Sandoz
  • Norway · Camcevi, Eligard
  • Poland · Eligard, Leuprostin
  • Portugal · Eligard, Lutrate Depot
  • Romania · Eligard, Leptoprol
  • Sweden · Eligard, Enanton Depot Dual
  • Slovenia · Eligard, Leptoprol
  • Slovakia · Eligard, Leuprorelin Sandoz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/abce75c1-9251-4d26-bd00-82c2e8bf01b2
GET /v1/drugs/abce75c1-9251-4d26-bd00-82c2e8bf01b2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unii": {
    "unii": "37JNS02E7V",
    "rxcui": "203217",
    "inchikey": "RGLRXNKKBLIBQS-XNHQSDQCSA-N",
    "display_name": "LEUPROLIDE ACETATE",
    "substance_type": "chemical",
    "ingredient_type": "INGREDIENT SUBSTANCE"
  },
  "route": "SUBCUTANEOUS",
  "livertox": {
    "summary": null,
    "livertox_id": null,
    "hepatotoxicity_score": 5
  },
  "spl_meta": {
    "008776cc-83f1-4f8c-819b-6471425da15f": {
      "match": "brand_token",
      "title": "VABRINTY (LEUPROLIDE ACETATE) INJECTION, SUSPENSION, EXTENDED RELEASE [URONOVA PHARMACEUTICALS, INC.]",
      "spl_version": "9",
      "published_date": "2026-01-28"
    }
  },
  "productid": "85043-030_b8da8614-75a8-453c-be31-0568da16a3b9",
  "productndc": "85043-030",
  "dosage_form": "INJECTION, SUSPENSION, EXTENDED RELEASE",
  "orange_book": {
    "appl_no": "021488",
    "products": [
      {
        "rs": true,
        "rld": true,
        "te_code": null,
        "strength": "30MG",
        "product_no": "001",
        "approval_date": "Feb 13, 2003"
      }
    ],
    "appl_type": "N"
  },
  "dea_schedule": null,
  "product_type": "HUMAN PRESCRIPTION DRUG",
  "substance_name": "LEUPROLIDE ACETATE",
  "proprietary_name": "Vabrinty",
  "active_ingred_unit": "mg/.5mL",
  "application_number": "NDA021488",
  "marketing_category": "NDA AUTHORIZED GENERIC",
  "nonproprietary_name": "Leuprolide acetate",
  "start_marketing_date": "20250804",
  "active_numerator_strength": "30"
}

See everything about leuprorelin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.